^{* All development phases not applicable for 505(b)2 regulatory filings.}

^{** Anticipated NDA submission based on current development timelines.}

^{*** See warnings and full prescribing information. For more information, visit www.onsolis.com.}

^{Marketed in the U.S. by Meda Pharmaceuticals.}

 Dr. Mark A. Sirgo will be presenting at the

Bank of America Merrill Lynch 2012 Health Care Conference

Thursday, May 17, 2012 at 11:20 a.m. PT (2:20 p.m. ET)

CLICK HERE FOR WEBCAST

__________________________________________

Treatment of Opioid Dependence:  The Future Role of BEMA Buprenorphine/Naloxone

 Wednesday, April 11, 2012 at 12:30 p.m. Eastern Time

CLICK HERE TO VIEW FULL PRESENTATION

  Click Here for a Slide Presentation